Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PRODUCT LIABILITY: SENATE JUDICIARY CMTE. HOLDING SEPT. 9 HEARING ON COMMERCE CMTE. BILL WITHOUT REFERRAL; DOLE SAYS S 2760 TO GET FULL SENATE REVIEW

Executive Summary

A Senate Judiciary Committee hearing scheduled for Sept. 9 will address Sen. Danforth's (R-Mo.) product liability bill (S 2760), even though the legislation has not been referred to the Judiciary Committee for review. Danforth's measure has been sent directly to the Senate floor and is expected to be considered after Congress reconvenes. It is highly unusual for a congressional committee to schedule a hearing on legislation when it has not received referral. Reportedly, the Administration asked Judiciary Committee Chairman Thurmond (R-S.C.) to hold the hearing. When Danforth introduced a clean version of the Commerce Committee-passed legislation on Aug. 14, he explained that negotiations for sequential referral to the Judiciary Committee had stalled. Danforth said Democratic members of the Judiciary Committee requested a 30-day referral initially, then referral until Sept. 12. The Commerce Committee instead offered two alternatives, Danforth said: "A straight 30-day referral; or a referral lasting through Sept. 12, conditioned on an agreement to limit debate on a motion to proceed to have the full Senate debate S 2760. Both alternatives were rejected." Danforth attempted to negotiate an agreement on limiting debate because it is considered likely that the bill will be filibustered if it is brought up on the Senate floor. Senate Majority Leader Dole (R-Kan.), speaking at the Small Business Conference on Aug. 21, said Senate consideration of S 2760 is a top priority. He also praised small business leaders for support for passage of product liability legislation and urged them to continue pressing Congress for legislative relief. If the bill is brought to the floor, any senator can extensively debate the motion to proceed with consideration. Opponents of the bill, particularly among consumerist groups and trial lawyers, can be expected to find a senator willing to filibuster S 2760. Dole would not be expected to allow a filibuster to continue beyond several hours before abandoning the bill. The House has not taken any action on product liability legislation. Rep. Waxman (D-Calif.), whose Commerce/Health Subcommittee has legislative jurisdiction over the issue, has indicated he will not schedule hearings until a Senate-passed bill is referred to the House. A clue to the House's attitude toward product liability legislation might be its Aug. 13 defeat of the Commercial Fishing Industry Vessel Safety and Insurance Act. The bill (HR 5013), which would limit fishing industry liability for businesses that provide for equitable compensation for employees who are injured on the job, was defeated under suspension of the rules by a 241-181 margin.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel